Key Takeaways From Teva Pharmaceutical Indus Analyst Ratings
Portfolio Pulse from Benzinga Insights
Teva Pharmaceutical Indus (NYSE:TEVA) has received mixed analyst ratings, with a recent trend towards bullish perspectives. Analysts have set a 12-month average price target of $23.75, reflecting a 10.47% increase from the previous target. Despite positive revenue growth, Teva faces challenges with profitability and returns, as indicated by below-average net margin, ROE, and ROA.
September 03, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva Pharmaceutical Indus has received a mix of bullish and somewhat bullish analyst ratings, with a 12-month average price target of $23.75, indicating a positive outlook. However, the company faces challenges with profitability and returns.
The majority of analysts have given bullish ratings, and the average price target has increased by 10.47%, suggesting a positive short-term outlook. However, financial metrics like net margin, ROE, and ROA are below industry averages, indicating potential challenges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100